Apollomics Inc. Class A Ordinary Shares
APLMApollomics Inc. is a biotechnology company focused on the development of innovative cancer therapies. It specializes in the discovery and advancement of immuno-oncology and targeted treatments, aiming to address unmet medical needs in oncology. The company's efforts include the development of clinical-stage drug candidates and leveraging its expertise in antibody engineering and immunology.
Company News
Apollomics Inc. reversed its wind-up plans after receiving $4.1 million in PIPE investments, appointed a new board and management team, and remains committed to continuing its global clinical trials for APL-101 (vebreltinib), a targeted oncology therapy.
Nasdaq Stock Market halted trading for Apollomics Inc. on September 17, 2025, at 14:37:17 Eastern Time, requesting additional information from the company.
Apollomics announced that its Phase 3 bridging trial of uproleselan in China for relapsed or refractory acute myeloid leukemia did not demonstrate a favorable benefit, with the median overall survival being lower in the uproleselan arm compared to the chemotherapy-only arm.
Apollomics reported progress in its vebreltinib program, including new data in non-CNS MET fusion tumors and NSCLC with MET amplification. The company also announced the closure of its uproleselan program due to negative Phase 3 results from its licensor, GlycoMimetics.
FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.
